Emmaus Life Sciences, Inc. (EMMA): Total Liabilities
$85.04M
As of 2025-12-31
$82.55M
As of 2026-06-30
+1.1%
3-year compound annual growth
+5.6%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $85.04M | +6.2% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $80.08M | -3.4% | 2026-03-31, Balance as of period end |
| 2023-12-31 | $82.94M | +0.8% | 2025-04-14, Balance as of period end |
| 2022-12-31 | $82.32M | +5.3% | 2024-07-03, Balance as of period end |
| 2021-12-31 | $78.18M | +20.9% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $64.69M | -8.2% | 2022-03-31, Balance as of period end |
| 2019-12-31 | $70.51M | n/a | 2021-08-10, Balance as of period end |
| 2019-09-30 | $70.35M | n/a | 2021-01-25, Balance as of period end |
| 2018-12-31 | $96.99M | n/a | 2021-01-25, Balance as of period end |
| 2018-09-30 | $1.87M | +20.4% | 2018-12-11, Balance as of period end |
| 2017-09-30 | $1.55M | -1.8% | 2018-12-11, Balance as of period end |
| 2016-09-30 | $1.58M | -70.8% | 2017-12-29, Balance as of period end |
| 2015-09-30 | $5.40M | +74.4% | 2016-12-22, Balance as of period end |
| 2014-09-30 | $3.10M | -13.0% | 2016-01-05, Balance as of period end |
| 2013-09-30 | $3.56M | -73.0% | 2014-12-29, Balance as of period end |
| 2012-09-30 | $13.20M | +11.9% | 2013-12-23, Balance as of period end |
| 2011-09-30 | $11.79M | +165.5% | 2013-01-15, Balance as of period end |
| 2010-09-30 | $4.44M | n/a | 2011-12-22, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $85.04M | +6.2% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $72.68M | +65.0% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $19.38M | -32.0% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $32.02M | +37.2% |
| Palatin Technologies Inc (PTN) | 2026-06-30 | $1.84M | -77.2% |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $57.01M | +28.3% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $5.49M | -10.4% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $38.11M | +4.6% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $18.04M | -47.5% |
Compare EMMA, PRLD, EVMN, TNXP side by side · Screen every company in Pharmaceutical Preparations ↗